home / stock / tak / tak news


TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 02/26/24

Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...

TAK - Championing Rare Voices on Rare Disease Day

Championing Rare Voices on Rare Disease Day Canada NewsWire 1 in 12 Canadians will be impacted by rare disease in their lifetime 1 I Am Number 12 campaign continues to drive action for rare disease community TORONTO , Feb. 26, 2024 /CNW/ - ...

TAK - (TAK) Technical Pivots with Risk Controls

2024-02-13 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

TAK - Takeda gets FDA approval for eosinophilic esophagitis drug

2024-02-12 14:38:53 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript CRISPR CMO who resigned after Casgevy approval lands...

TAK - FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older — EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and Intermittent Symptoms of Choking and Difficult or ...

TAK - Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial − TAK-861 Was Found to be Generally Safe and Well-Tolerated − Results Will be Presented at an Upcoming Scientific Congress Takeda ( TSE:4502/NYSE...

TAK - CRISPR CMO who resigned after Casgevy approval lands at Takeda

2024-02-02 17:11:18 ET More on CRISPR Therapeutics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off ...

TAK - Jefferies' Japan long equity list

2024-02-02 11:17:26 ET More on WisdomTree Japan Hedged Equity Fund: DXJ: Capitalizing On Japan's Bull Market, Mitigating FX Risk DXJ: Forward Indicator Is Showing Signs Of Weakness Tsunami warning in Japan after earthquake; Trading closed for New Year's Seeki...

TAK - Protagonist Therapeutics stock rises on Takeda license deal

2024-02-01 09:12:12 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shares gained around 6% premarket on Thursday after the biopharma firm entered into a global license and collaboration deal with Takeda ( NYSE: TAK ) for the development and commercialization of its inv...

TAK - Expected US Company Earnings on Thursday, February 1st, 2024

IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...

TAK - Takeda Pharmaceutical gets new CFO

2024-02-01 02:26:23 ET Takeda Pharmaceutical ( NYSE: TAK ) said that Costa Saroukos, CFO, has decided to leave Takeda to return to his home-country of Australia to be closer to family. ... Read the full article on Seeking Alpha For further details ...

Previous 10 Next 10